Companies/GRI Bio, Inc.
Company profile

GRI Bio, Inc.

NASDAQ: GRI · Healthcare · Biotechnology
PublicHQ La Jolla, CAReports USD
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$12.0M
Employees
4
as of 2026-08-28
Market cap
$177.0k
as of 2026-08-28

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$0$02025
Net income-$12.0M-$12.0M2025
Operating income-$12.0M-$12.0M2025
Total assets$8.7M$8.7M2025
Liabilities$2.7M$2.7M2025
Equity$6.0M$6.0M2025

Revenue trend

FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is GRI Bio, Inc.’s revenue?

GRI Bio, Inc. booked $0 in FY2025 revenue, contracting 100% year over yearamong the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Key facts
CEOW. Marc Hertz
SectorHealthcare
IndustryBiotechnology
HeadquartersLa Jolla, CA
ExchangeNASDAQ: GRI
Employees4
IPO date2021-02-10
Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.